Trial Profile
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Aspirin; Prasugrel
- Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke; Thrombosis; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms ISAR-REACT5
- 28 Aug 2023 Results of post-hoc analysis investigating the impact of ticagrelor and prasugrel on the incidence and pattern of repeat coronary revascularizations in patients with ACS undergoing percutaneous coronary intervention , presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 01 Apr 2023 Results of post hoc subgroup analysis assessing the efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome presenting during off- and on-hours, published in the Clinical Research in Cardiology.
- 03 Feb 2023 Status changed from active, no longer recruiting to completed.